Tonghua Dongbao Pharmaceutical Co (SHSE:600867) Construction In Progress: ¥193 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600867 Tonghua Dongbao Pharmaceutical Co Ltd SHSE:600867
83 GF Score
Price ¥8.17
GF Value ¥10.28
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Tonghua Dongbao Pharmaceutical Co Construction In Progress?

Tonghua Dongbao Pharmaceutical Co SHSE:600867 -0.85% 83 Construction In Progress is ¥193 Mil as of Mar. 2026. GuruFocus rates SHSE:600867 with a GF Score™ of 83/100 and a GF Value™ of ¥10.28 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Tonghua Dongbao Pharmaceutical Co's quarterly construction in progress increased from Sep. 2025 (¥154 Mil) to Dec. 2025 (¥170 Mil) and increased from Dec. 2025 (¥170 Mil) to Mar. 2026 (¥193 Mil).

Tonghua Dongbao Pharmaceutical Co's annual construction in progress declined from Dec. 2023 (¥1,319 Mil) to Dec. 2024 (¥226 Mil) and declined from Dec. 2024 (¥226 Mil) to Dec. 2025 (¥170 Mil).

Tonghua Dongbao Pharmaceutical Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Tonghua Dongbao Pharmaceutical Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonghua Dongbao Pharmaceutical Co Construction In Progress Chart

Tonghua Dongbao Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,203.39 1,157.64 1,319.50 226.11 169.50

Tonghua Dongbao Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 202.98 199.94 154.27 169.50 193.02
SHSE:600867
83GF Score
Tonghua Dongbao Pharmaceutical Co Ltd SHSE:600867
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tonghua Dongbao Pharmaceutical Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥193 Mil mean?
Tonghua Dongbao Pharmaceutical Co (SHSE:600867) has a Construction In Progress of ¥193 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Tonghua Dongbao Pharmaceutical Co and its competitors.
Is Tonghua Dongbao Pharmaceutical Co's Construction In Progress too high?
Tonghua Dongbao Pharmaceutical Co's current Construction In Progress is ¥193 Mil. Overall, Tonghua Dongbao Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tonghua Dongbao Pharmaceutical Co's Construction In Progress compare to ZTS and UTHR?
Tonghua Dongbao Pharmaceutical Co's Construction In Progress of ¥193 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Tonghua Dongbao Pharmaceutical Co and its competitors. Tonghua Dongbao Pharmaceutical Co's current Construction In Progress is ¥193 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonghua Dongbao Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Tonghua Dongbao Pharmaceutical Co (SHSE:600867) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.28, compared to a current price of ¥8.17 — trading 20.5% below its estimated fair value. The current Construction In Progress is ¥193 Mil. Tonghua Dongbao Pharmaceutical Co's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Tonghua Dongbao Pharmaceutical Co (SHSE:600867), the current Construction In Progress is ¥193 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tonghua Dongbao Pharmaceutical Co (SHSE:600867) Overvalued in 2026?

Based on GuruFocus' analysis, Tonghua Dongbao Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥8.17 is trading 20.5% below its estimated GF Value™ of ¥10.28. GuruFocus considers Tonghua Dongbao Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600867:

  • Construction In Progress: ¥193 Mil
  • GF Value™: ¥10.28 vs. price of ¥8.17 (20.5% below fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600867 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tonghua Dongbao Pharmaceutical Co Business Description

Address Dongbao Village, Jilin Province, Tonghua, CHN, 134123
Tonghua Dongbao Pharmaceutical Co Ltd is a China-based firm. Its engaged in the production and distribution of pharmaceutical products. Its products include human insulin injection, Heart and brain capsule, Vitamin e soft capsule, and Oral detoxification products.
83GF Score

Get the complete analysis for SHSE:600867

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.17
Price
¥10.28
GF Value